US Broker Ratings

AnaptysBio, Inc. (ANAB) Stock Analysis: Evaluating a Potential 58% Upside in Biotech Innovation

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company, is making waves in the healthcare sector with its cutting-edge immunology therapeutics. Based in San Diego, California, AnaptysBio focuses on developing innovative..

Geron Corporation (GERN): Investor Outlook with a Potential 217% Upside

Geron Corporation (NASDAQ: GERN), a biopharmaceutical company specializing in oncology therapeutics, is drawing significant attention from investors due to its promising pipeline and notable potential upside. With a current market..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring a Potential 211% Upside in the Healthcare Sector

Akebia Therapeutics, Inc. (NASDAQ: AKBA) presents an intriguing investment opportunity within the healthcare sector, specifically in the niche of drug manufacturers focusing on specialty and generic solutions. With a current..

Taysha Gene Therapies (TSHA): Exploring a 123.90% Potential Upside in Gene Therapy Revolution

Taysha Gene Therapies, Inc. (TSHA) is making waves in the biotechnology sector with its ambitious focus on developing adeno-associated virus-based gene therapies for severe monogenic diseases of the central nervous..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: A Closer Look at Its Steady Valuation and Strategic Direction

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presents an intriguing case for investors exploring opportunities in the biotechnology sector. With a market capitalization of $1.44 billion, this U.S.-based company has carved out..

CeriBell, Inc. (CBLL): Investor Outlook on Its Promising 52.25% Upside in the Medical Devices Sector

CeriBell, Inc. (NASDAQ: CBLL), a dynamic player in the healthcare sector, is capturing investor attention with a potential upside of 52.25% based on analyst price targets. This Sunnyvale, California-based company..

RxSight, Inc. (RXST) Stock Analysis: A 32.61% Potential Upside in the Innovative Medical Device Sector

RxSight, Inc. (NASDAQ: RXST) is carving out a niche in the healthcare sector with its innovative approach to cataract surgery, offering investors a unique opportunity to capitalize on groundbreaking technology..

HealthStream, Inc. (HSTM) Stock Analysis: A 18.79% Potential Upside Sparks Investor Interest

HealthStream, Inc. (NASDAQ: HSTM), a prominent player in the health information services industry, offers a suite of Software-as-a-Service (SaaS) applications tailored for healthcare organizations. With a market cap of $823.87..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Unveiling an 87% Upside Potential in Biotechnology

Iovance Biotherapeutics, Inc. (IOVA), a prominent player in the biotechnology sector, is capturing the attention of investors with its potential for significant upside. With a market capitalization of $2.09 billion,..

Trevi Therapeutics, Inc. (TRVI) Stock Report: Strong Buy Ratings Signal 42% Upside Potential

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company, is gaining significant attention in the investor community with an enticing potential upside of 42.29% based on its current trading price..

Immatics N.V. (IMTX) Stock Analysis: Exploring a 105% Upside Potential in the Biotech Sector

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company based in Tübingen, Germany, is capturing the attention of investors with its groundbreaking work in the field of T cell redirecting immunotherapies..

CorMedix Inc. (CRMD) Stock Analysis: Navigating a 100% Potential Upside in the Biotech Sector

CorMedix Inc. (NASDAQ: CRMD) is drawing significant attention in the biotechnology sector, and for good reason. With a compelling potential upside of 100.27%, this Parsippany, New Jersey-based company is making..

uniQure N.V. (QURE) Stock Analysis: Assessing Upside Potential and Analyst Confidence in Biotech Innovator

uniQure N.V. (QURE) stands out in the biotechnology sector with its innovative approach to treating rare and devastating diseases. Headquartered in Amsterdam, the company is renowned for its cutting-edge gene..

Nutex Health Inc. (NUTX): Investor Outlook on an Expansive Healthcare Player with a 65.69% Potential Upside

Navigating the vast landscape of healthcare investments can be daunting, but Nutex Health Inc. (NUTX) offers a compelling case for investors seeking growth within the Medical Care Facilities industry. With..

Phibro Animal Health Corporation (PAHC): Investor Outlook Reveals 23.46% Upside Potential

Phibro Animal Health Corporation (NASDAQ: PAHC), with its roots tracing back to 1946, has grown into a formidable player in the healthcare sector, particularly within the specialty and generic drug..

iRadimed Corporation (IRMD) Stock Analysis: Exploring a 23.94% Potential Upside in the Healthcare Sector

Investors looking for opportunities in the healthcare sector may find iRadimed Corporation (NASDAQ: IRMD) an intriguing prospect. With a market capitalization of $1.22 billion, this U.S.-based medical device company is..

Enliven Therapeutics, Inc. (ELVN): Investor Outlook Highlights 23.98% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is rapidly emerging as a noteworthy player in the biotechnology sector, captivating investors with a compelling narrative centered on innovation and potential upside. With a..

Weave Communications, Inc. (WEAV): Investor Outlook with 33% Upside Potential

Weave Communications, Inc. (NYSE: WEAV), a player in the healthcare sector specializing in health information services, presents an intriguing opportunity for investors looking to capitalize on the growing digital healthcare..

Intellia Therapeutics, Inc. (NTLA)

⚠️ No article content returned.

..

Syndax Pharmaceuticals, Inc. (SNDX) Growth Potential: Analysts Forecast a 102.54% Upside

Investors with a keen eye on the biotechnology sector should take note of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX), a promising player in the healthcare industry. With a current market capitalization..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds